• 1
    National Diabetes Information Clearinghouse (NDIC). National Diabetes Statistics. http:diabetes.niddk.nih.govdmpubsstatistics. Accessed February 21, 2005.
  • 2
    Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004;116(suppl 5A):30S38S.
  • 3
    Eguchi K, Kario K, Shimada K. Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. Stroke. 2003; 34:24712474.
  • 4
    Yuyun MF, Khaw KT, Luben R, et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol. 2004; 159:284293.
  • 5
    Davis TM, Millns H, Stratton IM, et al. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med. 1999; 159:10971103.
  • 6
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290:199206.
  • 7
    Hall WD, Clark LT, Wenger NK, et al. The metabolic syndrome in African Americans: a review. Ethn Dis. 2003; 13:414428.
  • 8
    Bonds DE, Zaccaro DJ, Karter AJ, et al. Ethnic and racial differences in diabetes care: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2003; 26:10401046.
  • 9
    Franklin SS. Definition and epidemiology of hypertensive cardiovascular disease in women: the size of the problem. J Hypertens. 2002; 20(suppl):S3S5.
  • 10
    Hu FB, Stampfer MJ, Colomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women. Arch Intern Med. 2001; 161:17171723.
  • 11
    Sesso HD, Chen RS, L'Italien GJ, et al. Blood pressure lowering and life expectancy based on a Markov model of cardiovascular events. Hypertension. 2003; 42:885890.
  • 12
    Curb JD, Pressel SL, Cutler JA, et al. Effect of diureticbased antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Research Group. JAMA. 1996; 276:18861892.
  • 13
    Hansson L, Janchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998; 351:17551762.
  • 14
    Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317:703713.
  • 15
    Gasowski J, Birkenhager WH, Staessen JA, et al. Benefit of antihypertensive treatment in diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) trial. Cardiovasc Drugs Ther. 2000; 14:4953.
  • 16
    Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002; 359:10041010.
  • 17
    Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42:12061252.
  • 18
    Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291:335342.
  • 19
    Basile JN, Lackland DT, Basile JM, et al. A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. J Clin Hypertens (Greenwich). 2004; 6:1825.
  • 20
    Consensus Statement of the Hypertension in African Americans Working Group of the International Society of Hypertension in Blacks. Management of high blood pressure in African Americans. Arch Intern Med. 2003; 163:525541.
  • 21
    Hall WD, Ferrario CM, Moore MA, et al. Hypertensionrelated morbidity and mortality in the southeastern United States. Am J Med Sci. 1997; 313:195209.
  • 22
    Rehman SU, Hutchison FN, Hendrix K, et al. Ethnic differences in blood pressure control among men at Veterans Affairs clinics and other health care sites. Arch Intern Med. 2005; 165:10411047.
  • 23
    Singer GM, Izhar M, Black HR. Guidelines for hypertension: are quality-assurance measures on target? Hypertension. 2004; 43:198202.
  • 24
    Intercooled Stata for Windows. College Station , TX : Stata Corporation; 2003. Available at: http:www.stata.comproductswindows.html. Accessed March 20, 2005.
  • 25
    Abbott KC, Bakris GL. What have we learned from the current trials? Med Clin North Am. 2004; 88:189207.
  • 26
    Richardson AD, Piepho RW. Effect of race and hypertension and antihypertensive therapy. Int J Clin Pharmacol Ther. 2000; 38:7579.
  • 27
    Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004; 141:614627.
  • 28
    Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288:24212431.
  • 29
    Bakris GL, Williams M, Dworkin L, et al., for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646661.
  • 30
    Tu K, Davis D. Can we alter physician behavior by educational methods? Lessons learned from studies of the management and follow-up of hypertension. J Contin Educ Health Prof. 2002; 22:1122.